- Home
- PRAX vs XPEL Comparison
PRAX vs XPEL Comparison
Compare PRAX & XPEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- XPEL
- Stock Information
- Founded
- PRAX 2015
- XPEL 1999
- Country
- PRAX United States
- XPEL United States
- Employees
- PRAX N/A
- XPEL N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- XPEL Industrial Specialties
- Sector
- PRAX Health Care
- XPEL Industrials
- Exchange
- PRAX Nasdaq
- XPEL Nasdaq
- Market Cap
- PRAX 950.8M
- XPEL 984.3M
- IPO Year
- PRAX 2020
- XPEL N/A
- Fundamental
- Price
- PRAX $59.22
- XPEL $35.35
- Analyst Decision
- PRAX Strong Buy
- XPEL Strong Buy
- Analyst Count
- PRAX 10
- XPEL 1
- Target Price
- PRAX $101.00
- XPEL $58.00
- AVG Volume (30 Days)
- PRAX 399.5K
- XPEL 147.9K
- Earning Date
- PRAX 08-12-2025
- XPEL 08-06-2025
- Dividend Yield
- PRAX N/A
- XPEL N/A
- EPS Growth
- PRAX N/A
- XPEL N/A
- EPS
- PRAX N/A
- XPEL 1.71
- Revenue
- PRAX $8,122,000.00
- XPEL $434,101,000.00
- Revenue This Year
- PRAX N/A
- XPEL $11.20
- Revenue Next Year
- PRAX $4,434.72
- XPEL $11.18
- P/E Ratio
- PRAX N/A
- XPEL $20.71
- Revenue Growth
- PRAX 270.02
- XPEL 8.38
- 52 Week Low
- PRAX $26.70
- XPEL $24.25
- 52 Week High
- PRAX $91.83
- XPEL $48.58
- Technical
- Relative Strength Index (RSI)
- PRAX 78.36
- XPEL 46.84
- Support Level
- PRAX $53.89
- XPEL $34.33
- Resistance Level
- PRAX $59.10
- XPEL $35.90
- Average True Range (ATR)
- PRAX 3.26
- XPEL 1.23
- MACD
- PRAX 0.59
- XPEL -0.14
- Stochastic Oscillator
- PRAX 88.19
- XPEL 26.07
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About XPEL XPEL Inc.
XPEL Inc is a supplier of protective films, coatings, and related services to the automobile aftermarket, new car dealerships, and automobile original equipment manufacturers, or OEMs. The majority of its revenue is derived from the sale of automotive products and related services while the remainder of its revenue is derived from non-automotive products including architectural window film and marine and flat surface protection films. The majority of revenue is derived from the United States.